SEMD1
CMGANTi003-A
General
Cell Line |
|
| hPSCreg name | CMGANTi003-A |
| Cite as: | CMGANTi003-A (RRID:CVCL_C1SW) |
| Alternative name(s) |
SEMD1
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
RCMGi011-A (P10L1) Donor diseases: Mucopolysaccharidosis Type IVB autosomal recessive nonsyndromic deafness 12 RCMGi011-B (P10L2) Donor diseases: Mucopolysaccharidosis Type IVB autosomal recessive nonsyndromic deafness 12 |
| Last update | 12th January 2023 |
| User feedback | |
Provider |
|
| Generator | Center of Medical Genetics Antwerp (CMGANT) |
| Owner | Center of Medical Genetics Antwerp (CMGANT) |
| Distributors | |
| Derivation country | Belgium |
External Databases |
|
| BioSamples | SAMEA14369850 |
| Cellosaurus | CVCL_C1SW |
| Wikidata | Q114310968 |
General Information |
|
| Publications | |
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
Donor Information
General Donor Information |
|
| Sex | male |
| Ethnicity | Italian |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
| Disease associated phenotypes |
|
| Family history | Yes |
| Is the medical history available upon request? | Publication Cho et al. BGN Mutations in X-Linked Spondyloepimetaphyseal Dysplasia |
| Is clinical information available? | Publication Cho et al. BGN Mutations in X-Linked Spondyloepimetaphyseal Dysplasia |
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Yes
46, XY. No clinically significant abnormalities observed.
Karyotyping method:
Molecular karyotyping by SNP array
http:// |
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
Yes
SNP typing array
Dermal fibroblast DNA sample was genotyped with a HumanCytoSNP-12 assay (Illumina). No clinically significant CNVs observed. |
Donor Relations |
|
| All cell lines of this donor's relatives |
Has brother:
|
External Databases (Donor) |
|
| BioSamples | SAMEA14369897 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
| If you do not hold the Donor Consent Form, do you know who does? | Yes |
| Alternatives to consent are available? | Yes |
| Alternatives to consent | |
| Alternative consent approval number | |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| How may genetic information associated with the cell line be accessed? | Controlled Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? | Yes |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Ethical committee Antwerp University Hospital |
| Approval number | 11/8/79 2018.09.17 |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
| Source cell type | |
| Passage number reprogrammed | 2 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Is reprogramming vector detectable? |
No |
| Methods used |
PCR
|
Vector free reprogramming |
|
Other |
|
| Selection criteria for clones | Clones were manually picked and further expanded using 0.5mM EDTA based on their morphology characteristics (round colonies with smooth edges). Only clones with desired morphology and no differentiation were selected for cryopreservation. |
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
Yes |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzyme-free cell dissociation
EDTA
|
| O2 Concentration | 5 % |
| CO2 Concentration | 5 % |
| Medium |
Essential 8™ Flex
|
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| POU5F1 (OCT-4) |
Yes |
|
|
|||
| NANOG |
Yes |
|
|
|||
| TRA 1-60 |
Yes |
|
||||
| TRA 1-81 |
Yes |
|
||||
| SOX2 |
Yes |
|
|
Score:
| Marker | Present | Absent |
| mCpG | ||
| OCT4 |
Differentiation Potency
In vitro directed differentiation
In vitro directed differentiation
In vitro directed differentiation
Microbiology / Virus Screening |
|
| Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
46, XY. No clinically relevant abnormalities observed.
Passage number: 11
Karyotyping method:
Molecular karyotyping by SNP array
http:// |
Other Genotyping (Cell Line) |
|
| Is there genome-wide genotyping or functional data available? |
Yes
SNP typing array
DNA sample was genotyped with a HumanCytoSNP-12 assay (Illumina). No clinically significant CNVs observed. |
Login to share your feedback, experiences or results with the research community.